Stock Research for FMS

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

FMS Stock Chart & Research Data

The FMS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the FMS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


FMS Due diligence Resources & Stock Charts

The FMS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View FMS Detailed Price Forecast - CNN Money CNN View FMS Detailed Summary - Google Finance
Yahoo View FMS Detailed Summary - Yahoo! Finance Zacks View FMS Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View FMS Trends & Analysis - Trade-Ideas Barrons View FMS Major Holders - Barrons
NASDAQ View FMS Call Transcripts - NASDAQ Seeking View FMS Breaking News & Analysis - Seeking Alpha
Spotlight View FMS Annual Report - CompanySpotlight.com OTC Report View FMS OTC Short Report - OTCShortReport.com
TradeKing View FMS Fundamentals - TradeKing Charts View FMS SEC Filings - Bar Chart
WSJ View Historical Prices for FMS - The WSJ Morningstar View Performance/Total Return for FMS - Morningstar
MarketWatch View the Analyst Estimates for FMS - MarketWatch CNBC View the Earnings History for FMS - CNBC
StockMarketWatch View the FMS Earnings - StockMarketWatch MacroAxis View FMS Buy or Sell Recommendations - MacroAxis
Bullish View the FMS Bullish Patterns - American Bulls Short Pains View FMS Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View FMS Stock Mentions - StockTwits PennyStocks View FMS Stock Mentions - PennyStockTweets
Twitter View FMS Stock Mentions - Twitter Invest Hub View FMS Investment Forum News - Investor Hub
Yahoo View FMS Stock Mentions - Yahoo! Message Board Seeking Alpha View FMS Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for FMS - SECform4.com Insider Cow View Insider Transactions for FMS - Insider Cow
CNBC View FMS Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for FMS - OTC Markets
Yahoo View Insider Transactions for FMS - Yahoo! Finance NASDAQ View Institutional Holdings for FMS - NASDAQ


Stock Charts

FinViz View FMS Stock Insight & Charts - FinViz.com StockCharts View FMS Investment Charts - StockCharts.com
BarChart View FMS Stock Overview & Charts - BarChart Trading View View FMS User Generated Charts - Trading View


Latest Financial News for FMS

Is Fresenius Medical Care AG & Co KGaA (ETR:FME) A Buy At Its Current PE Ratio?
Posted on Wednesday June 20, 2018

The content of this article will benefit those of you who are starting to educate yourself about investing in the stock market and want to better understand how you canRead More...


FMC takes stake in Humacyte in bet on bioengineered blood vessel
Posted on Monday June 11, 2018

Germany's Fresenius Medical Care (FMC) (FMEG.DE) has agreed to take a $150 million (112.3 million pounds) stake in U.S. tissue engineering firm Humacyte Inc. and will become the exclusive distributor of the company's bioengineered blood vessels once they win approval. The world's largest provider of kidney dialysis, FMC is banking on the alliance to lead to better ways of accessing patients' blood vessels, a delicate medical procedure that is part of providing life-saving dialysis, the company said in a statement on Monday. FMC will take a 19 percent stake in the privately held company.


Durham’s Humacyte lands $150M from Fresenius Medical Care
Posted on Monday June 11, 2018

Durham-based Humacyte has landed a $150 million equity investment from Fresenius Medical Care. According to the companies, the investment will see Fresenius (NYSE: FMS) take a 19 percent fully diluted ownership stake in Humacyte and obtain the exclusive global rights to commercialize Humacyte’s human acellular vessel Humacyl upon approval by certain health authorities.  “Humacyte is at this true inflection point in the development of our blood vessel,” says Humacyte Chief Medical Officer Dr. Jeff Lawson.


Fresenius Medical Care and Humacyte announce strategic global partnership supported by a $150M equity investment
Posted on Monday June 11, 2018

BOSTON, June 11, 2018 /PRNewswire/ -- Fresenius Medical Care, the world's largest provider of dialysis products and services, and Humacyte, Inc., a medical research, discovery and development company, today announced a strategic, global partnership and a $150M USD equity investment. This agreement has the potential to make Humacyte's investigational human acellular vessel, HUMACYL®, available to more patients worldwide following approval of the product. HUMACYL is currently being investigated for vascular access for hemodialysis and may prove more effective than current synthetic grafts and fistula.


Enter a stock symbol to view the stock details.